Merck & Co. (MRK)
(Delayed Data from NYSE)
$103.46 USD
+0.98 (0.96%)
Updated Dec 1, 2023 04:00 PM ET
After-Market: $103.45 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
MRK 103.46 +0.98(0.96%)
Will MRK be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study
Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More
Merck (MRK) to Acquire Private Neuroscience Company for $610M
Other News for MRK
Dividend Champion, Contender, And Challenger Highlights: Week Of December 3
Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments
Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
5 Relatively Secure And Cheap Dividend Stocks To Invest In - December 2023